Kunal Malik

Single-cell transcriptome landscape of circulating CD4+ T cell populations in autoimmune diseases

Telemedicine for healthcare: Capabilities, features, barriers, and applications

The JAK/STAT signaling pathway: from bench to clinic

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib

T cells and the skin: from protective immunity to inflammatory skin disorders

Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression

Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis

Biological Therapies for Atopic Dermatitis: A Systematic Review

Improving Access to Care: Telemedicine Across Medical Domains

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors

Immunology of Acute and Chronic Wound Healing

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis

Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis

Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases

Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Ocular Findings at Two Health Centers